{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:26:15Z","timestamp":1793179575611,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00259-023-06557-x","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T10:01:45Z","timestamp":1702548105000},"page":"1297-1309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["[18F]FDG PET\/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica"],"prefix":"10.1007","volume":"51","author":[{"given":"Bastien","family":"Allard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Tison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Boukhlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Guellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Jousse-Joulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Marhadour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Le Pennec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Sala\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-2696","authenticated-orcid":false,"given":"Sol\u00e8ne","family":"Querellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"6557_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/art.34356","volume":"64","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64:943\u201354.","journal-title":"Arthritis Rheum"},{"key":"6557_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71:484\u201392.","journal-title":"Ann Rheum Dis"},{"key":"6557_CR3","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.39333","volume":"67","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Arthritis Rheumatol Hoboken NJ. 2015;67:2569\u201380.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"6557_CR4","first-page":"65","volume":"32","author":"HM Kremers","year":"2005","unstructured":"Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32:65\u201373.","journal-title":"J Rheumatol"},{"key":"6557_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.21311","volume":"53","author":"HM Kremers","year":"2005","unstructured":"Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Direct medical costs of polymyalgia rheumatica. Arthritis Rheum. 2005;53:578\u201384.","journal-title":"Arthritis Rheum"},{"key":"6557_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli M, Radner H, Kerschbaumer A, Mrak D, Durechova M, Stieger J, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial. Ann Rheum Dis. 2022;81:838\u201344.","journal-title":"Ann Rheum Dis"},{"key":"6557_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet M-E, Wendling D, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022;328:1053\u201362.","journal-title":"JAMA"},{"key":"6557_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00259-015-3287-z","volume":"43","author":"X Palard-Novello","year":"2016","unstructured":"Palard-Novello X, Querellou S, Gouillou M, Saraux A, Marhadour T, Garrigues F, et al. Value of (18)F-18F-FDG PET\/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Eur J Nucl Med Mol Imaging. 2016;43:773\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6557_CR9","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec V, Berthelot JM, Cornec D, Renaudineau Y, Marhadour T, Jousse-Joulin S, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75:1506\u201310.","journal-title":"Ann Rheum Dis"},{"key":"6557_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jbspin.2016.07.003","volume":"83","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec V. Has the time come for biotherapies in giant cell arteritis and polymyalgia rheumatica? Joint Bone Spine. 2016;83:471\u20132.","journal-title":"Joint Bone Spine"},{"key":"6557_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","volume":"121","author":"J Deng","year":"2010","unstructured":"Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906\u201315.","journal-title":"Circulation"},{"key":"6557_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","volume":"9","author":"CM Weyand","year":"2013","unstructured":"Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9:731\u201340.","journal-title":"Nat Rev Rheumatol"},{"key":"6557_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/BOR.0b013e32833ee946","volume":"23","author":"CM Weyand","year":"2011","unstructured":"Weyand CM, Younge BR, Goronzy JJ. IFN-\u03b3 and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23:43\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"164","key":"6557_CR14","first-page":"5319","volume":"2000","author":"EL Masteller","year":"1950","unstructured":"Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol Baltim Md. 1950;2000(164):5319\u201327.","journal-title":"J Immunol Baltim Md"},{"key":"6557_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.immuni.2006.03.001","volume":"24","author":"JA Bluestone","year":"2006","unstructured":"Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006;24:233\u20138.","journal-title":"Immunity"},{"key":"6557_CR16","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/art.21206","volume":"52","author":"RQ Cron","year":"2005","unstructured":"Cron RQ. A signal achievement in the treatment of arthritis. Arthritis Rheum. 2005;52:2229\u201332.","journal-title":"Arthritis Rheum"},{"key":"6557_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907\u201315.","journal-title":"N Engl J Med"},{"key":"6557_CR18","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114\u201323.","journal-title":"N Engl J Med"},{"key":"6557_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A Randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol Hoboken NJ. 2017;69:837\u201345.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"6557_CR20","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","volume":"73","author":"CA Langford","year":"2014","unstructured":"Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s). Ann Rheum Dis. 2014;73:1376\u20139.","journal-title":"Ann Rheum Dis"},{"key":"6557_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol Hoboken NJ. 2017;69:846\u201353.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"6557_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86\u201394.","journal-title":"Ann Rheum Dis"},{"key":"6557_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","volume":"47","author":"P-Y Sala\u00fcn","year":"2020","unstructured":"Sala\u00fcn P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET\/CT\/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:28\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6557_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/623036","volume":"2013","author":"AWJM Glaudemans","year":"2013","unstructured":"Glaudemans AWJM, de Vries EFJ, Galli F, Dierckx RAJO, Slart RHJA, Signore A. The use of (18)F-18F-FDG-PET\/CT\/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013: 623036.","journal-title":"Clin Dev Immunol"},{"key":"6557_CR25","doi-asserted-by":"crossref","unstructured":"Slart RHJA, Writing group, Reviewer group, Members of EANM Cardiovascular, Members of EANM Infection & Inflammation, Members of Committees, SNMMI Cardiovascular, et al. 18F-FDG-PET\/CT\/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET\/CT Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45:1250\u201369.","DOI":"10.1007\/s00259-018-3973-8"},{"key":"6557_CR26","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s00259-020-05162-6","volume":"48","author":"KSM van der Geest","year":"2021","unstructured":"van der Geest KSM, Treglia G, Glaudemans AWJM, Brouwer E, Jamar F, Slart RHJA, et al. Diagnostic value of [18F]18F-FDG-PET\/CT\/CT in polymyalgia rheumatica: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:1876\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6557_CR27","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","volume":"46","author":"D Blockmans","year":"2007","unstructured":"Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. RePET\/CTitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatol Oxf Engl. 2007;46:672\u20137.","journal-title":"Rheumatol Oxf Engl"},{"key":"6557_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63:1279\u201383.","journal-title":"Ann Rheum Dis"},{"key":"6557_CR29","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1136\/ard.2002.002618","volume":"62","author":"BF Leeb","year":"2003","unstructured":"Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis. 2003;62:1189\u201394.","journal-title":"Ann Rheum Dis"},{"key":"6557_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.22630","volume":"57","author":"A Binard","year":"2007","unstructured":"Binard A, De Bandt M, Berthelot J-M, Saraux A. Inflammatory Joint Disease Working Group CRI of the French Society for Rheumatology. Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum. 2007;57:481\u20136.","journal-title":"Arthritis Rheum."},{"key":"6557_CR31","doi-asserted-by":"crossref","unstructured":"Binard A, Lefebvre B, De Bandt M, Berthelot J-M, Saraux A, Club \u201cRhumatismes et Inflammation.\u201d Validity of the polymyalgia rheumatica activity score in primary care practice. Ann Rheum Dis. 2009;68:541\u20135.","DOI":"10.1136\/ard.2008.088526"},{"key":"6557_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3899\/jrheum.110866","volume":"39","author":"C Cleuziou","year":"2012","unstructured":"Cleuziou C, Binard A, De Bandt M, Berthelot J-M, Saraux A. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol. 2012;39:310\u20133.","journal-title":"J Rheumatol"},{"key":"6557_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","volume":"90","author":"A Chalaris","year":"2011","unstructured":"Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol. 2011;90:484\u201394.","journal-title":"Eur J Cell Biol"},{"key":"6557_CR34","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/rheumatology\/kex477","volume":"57","author":"V Devauchelle-Pensec","year":"2018","unstructured":"Devauchelle-Pensec V, Saraux L, Berthelot JM, De Bandt M, Cornec D, Guellec D, et al. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatol Oxf Engl. 2018;57:666\u201370.","journal-title":"Rheumatol Oxf Engl"},{"key":"6557_CR35","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/rheumatology\/kex376","volume":"57","author":"L Henckaerts","year":"2018","unstructured":"Henckaerts L, Gheysens O, Vanderschueren S, Goffin K, Blockmans D. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica-a prospective study of 99 patients. Rheumatol Oxf Engl. 2018;57:1908\u201316.","journal-title":"Rheumatol Oxf Engl"},{"key":"6557_CR36","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/rheumatology\/keab483","volume":"61","author":"KSM van der Geest","year":"2022","unstructured":"van der Geest KSM, van Sleen Y, Nienhuis P, Sandovici M, Westerdijk N, Glaudemans AWJM, et al. Comparison and validation of 18F-FDG-PET\/CT\/CT scores for polymyalgia rheumatica. Rheumatol Oxf Engl. 2022;61:1072\u201382.","journal-title":"Rheumatol Oxf Engl"},{"key":"6557_CR37","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/rheumatology\/kew202","volume":"55","author":"M Sondag","year":"2016","unstructured":"Sondag M, Guillot X, Verhoeven F, Blagosklonov O, Prati C, Boulahdour H, et al. Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. Rheumatol Oxf Engl. 2016;55:1452\u20137.","journal-title":"Rheumatol Oxf Engl"},{"key":"6557_CR38","unstructured":"Saraux A, Le Henaff C, Dernis E, Carvajal Alegria G, Alice Tison, Quere B, et al. Abatacept in the Early-Onset Polymyalgia Rheumatica Study (ALORS): a proof-of-concept randomized trial. Lancet Rhumatol. In press."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06557-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06557-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06557-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:05:06Z","timestamp":1711019106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06557-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["6557"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06557-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee by the appropriate ethics committee (CPP Sud-Est II Ref CPP: 2018\u201333).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of the images in Figs. 1, 4, and 5<i>.<\/i>","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Valerie Devauchelle Speakers Bureau: Abbvie, BMS, Galapagos, Lilly, Novartis, Pfizer, Sanofi, Grant\/Research Support from BMS.Alain Saraux Speakers Bureau: Abbvie, BMS, Galapagos, Lilly, Novartis, Nordic, Pfizer, Roche-Chugai, Sanofi, UCB, Grant\/Research Support from Abbvie, BMS, Lilly, Novartis.Nowak Emmanuel: None Declared.Sandrine Jousse-Joulin Speakers Bureau: Abbvie, Amgen, Astra Zeneca, BMS, Galapagos, Janssen, Pfizer, UCB, Novartis, MSD, GSK, Sanofi.Thierry Marhadour: Abbvie, Amgen, Chuga\u00ef, Lilly, Mylan, Novartis, Pfizer.The other authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}